Axon’s Pause: A Fleeting Shadow?

by

The markets, dear reader, are a peculiar beast. One expects a steady climb, a predictable ascent towards… well, towards something resembling prosperity. But no. They cough, they sputter, they occasionally lapse into fits of melancholy, much like old Mr. Petrovich, the bookkeeper down the street, after a particularly strong batch of pickled herring. For nine years, Axon Enterprise, purveyor of those curious electrical prods and increasingly sophisticated surveillance apparatus, defied this melancholic trend. A streak, you see, a veritable parade of gains. But the parade, alas, has paused. A single year of decline – a mere 4% – and the financial scribes are already sharpening their quills, preparing obituaries for a company that, by all accounts, remains stubbornly, almost offensively, alive.

The S&P 500, that grand, lumbering index, experiences such hiccups with regularity – about once every four years, a gentle reminder that even empires crumble, if only momentarily. But Axon, for nearly a decade, seemed immune. It expanded, naturally, beyond the simple TASER, branching into the realm of body cameras, dashboard cameras, and the management of evidence – a veritable panopticon for the modern age. A surge, a veritable blossoming of stock value, occurred – a 3,340% increase over the period from 2015 to 2024. One suspects a clerical error, perhaps a rogue decimal point, but the numbers, alas, hold firm.

That late surge in 2024, however, may have been its undoing. A stock inflated with expectation, like a poorly constructed balloon, is prone to bursting. The 4% decline in 2025, while seemingly insignificant, was enough to break the streak. More troubling, it underperformed the S&P 500 for the first time since 2017. A scandal, one might assume, or a catastrophic flaw in their products. But no. The market, it seems, simply grew weary of relentless success. It prefers a little suffering, a touch of drama, a hint of the absurd.

Where Axon Stands Now

The slump, one suspects, is less a reflection of the company’s fundamentals and more a consequence of its own ambition. The stock, you see, had doubled in the second half of 2024, achieving a valuation that bordered on the fantastical. Revenue growth, however, remains robust, exceeding 30% in the last seven quarters, a feat that would impress even the most jaded of accountants. The price-to-sales ratio, admittedly, has jumped from a modest 4 a decade ago to a rather extravagant 19 today. It’s as if the company is attempting to build a palace on a foundation of air.

Yet, there are catalysts for growth. Acquisitions, for instance. Prepared and Carbyne, two platforms that have enabled the launch of Axon 911, a system that utilizes artificial intelligence to streamline emergency response. It’s a grand vision, to connect all parties involved in an emergency call in real-time. One shudders to think of the bureaucratic complexities involved, the endless forms, the inevitable misunderstandings. The company claims this expands its addressable market by $5 billion, bringing the total to $159 billion. A sum so large, it feels almost… obscene.

And then there’s Draft One, a generative AI product that writes first drafts of police reports based on footage from body cameras. It frees up officers, the company claims, to focus on more valuable tasks. One imagines a future where police work is entirely automated, conducted by algorithms and robots. A chilling thought, perhaps, but undeniably efficient. It’s as if Axon is attempting to build a self-governing police state, powered by artificial intelligence.

They’ve even begun expanding the market for their body cameras, securing their largest sale ever to a package delivery company for their frontline workers. One envisions a fleet of delivery drivers, each equipped with a miniature surveillance apparatus, documenting every interaction, every package delivered. It’s a world of constant monitoring, a panopticon extended to the mundane tasks of everyday life.

Loading widget...

A Return to Form?

As a business, Axon appears remarkably healthy, despite the recent setback. The slump, one suspects, is merely a temporary aberration, a fleeting shadow cast by its own success. The company has played the long game with remarkable skill, making strategic moves to pave the way for sustained growth. It’s a good bet, therefore, that Axon will return to its winning ways this year, and continue to outperform over the long term. Though, one must always remember, the markets are fickle beasts, prone to sudden whims and irrational behavior. And sometimes, the most logical course of action is simply to accept the absurdity of it all.

Read More

2026-01-27 08:52